SKSergey Andreyevich Klimin

Sergey Andreyevich Klimin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergey Andreyevich Klimin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative assessment of quality of life in patients receiving intraperitoneal aerosol chemotherapy under pressure for gastric cancer with peritoneal dissemination

    by Sergei A. Klimin, Yan I. Kolesnik, Shamama E. Mustafaeva, Nikolai M. Kiselev, Irina S. Shumskaya, Vladimir E. Zagainov, Sergei V. Gamayunov, Гамаюнов Сергей Викторович

    AIM: To assess and compare quality of life in patients with stage IV gastric cancer and peritoneal dissemination receiving systemic PCT versus combined treatment (systemic PCT + PIPAC). METHODS: A prospective randomized study (protocol NCT06313801) enrolled 72 patients: 39 in the systemic PCT group and 33 in the PCT + PIPAC group. Quality of life was assessed using the standardized EORTC QLQ-C30 questionnaire at five time points: before treatment, after 3 and 6 courses, and 3 and 6 months after completion of treatment. Analysis was performed using multivariate analysis of variance with repeated measures. Changes in QOL were presented using an error bar plot. RESULTS: At baseline, groups had comparable indicators (p = 0.297). Statistically significant differences in favor of the PCT + PIPAC group were detected from the third to fifth measurement (QOL3: p = 0.009; QOL4: p = 0.006; QOL5: p = 0.031). Similar results were obtained in the subgroup with positive peritoneal lavage without macroscopic carcinomatosis (Cy+) (QOL3: p = 0.005; QOL4: p = 0.015; QOL5: p = 0.013). In subgroups with macroscopic peritoneal dissemination (PCI 1-7 and PCI 8-15), no statistically significant differences were detected (p 0.24 and p 0.18). CONCLUSION: Addition of PIPAC to systemic PCT in patients with positive peritoneal lavage leads to a statistically significant improvement in quality of life indicators. In patients with macroscopic peritoneal carcinomatosis, addition of PIPAC does not worsen quality of life compared with systemic PCT. TRANSLATE with x English Arabic Hebrew Polish Bulgarian Hindi Portuguese Catalan Hmong Daw Romanian Chinese Simplified Hungarian Russian Chinese Traditional Indonesian Slovak Czech Italian Slovenian Danish Japanese Spanish Dutch Klingon Swedish English Korean Thai Estonian Latvian Turkish Finnish Lithuanian Ukrainian French Malay Urdu German Maltese Vietnamese Greek Norwegian Welsh Haitian Creole Persian TRANSLATE with COPY THE URL BELOW Back EMBED THE SNIPPET BELOW IN YOUR SITE Enable collaborative features and customize widget: Bing Webmaster Portal Back

  • CLINICAL OBSERVATION OF TREATING GASTRIC CANCER WITH PERITONEAL METASTASES: PRESSURIZED INTRAPERITONEAL DOCETAXEL ADMINISTRATION

    by Sergey Andreyevich Klimin, Sergey Viktorovich Gamayunov, Yuliya Aleksandrovna Petryakova, Roman Andreyevich Gagayev, Vladimir Yevgen'YEvich Zagaynov, Nikolay Mikhaylovich Kiselev

    Peritoneal dissemination is one of the most frequent metastatic pattern of advanced gastric cancer. Currently, its prognosis remains poor. It is possible to improve treatment outcomes in a carefully selected group of patients through a combination of systemic and local therapies. This publication presents a clinical case of peritoneal disseminated gastric cancer treatment using a combination of systemic triple chemotherapy and pressurized intraperitoneal aerosol chemotherapy with docetaxel. Objective. The aim of the article is to study the treatment outcomes for metastatic gastric cancer with peritoneal dissemination using pressurized intraperitoneal docetaxel injection (clinical case study). Materials and Methods. We assessed the tolerability, efficacy, and safety of the treatment method used, the pathological response of peritoneal lesions, the primary tumor, and quality of life during treatment and the follow-up period. The example was a clinical case of stage IV gastric cancer treatment, cT4aN1M1 (Cy+, per+ PCI 5) using the FLOT regimen (3 cycles) + (mFLOT (3 cycles) + dPIPAC) regimen. Results. The study demonstrates successful application of docetaxel via pressurized intraperitoneal aerosol administration as part of systemic treatment in first-line chemotherapy. After achieving complete pathomorphological regression of gastric cancer peritoneal metastases using systemic chemotherapy and pressurized intraperitoneal chemotherapy, surgical treatment resulted in no surgical complications or deterioration in quality of life during a 1-year follow-up period Conclusion. Given the limited treatment options for patients with gastric cancer and peritoneal dissemination, the proposed method may become a viable therapeutic option.

  • Open Access

    Cachexia and its impact on early postoperative results in patients with resectable gastric cancer

    by V. K. Lyadov, T. S. Boldyreva, S. V. Gamayunov, V. E. Zagainov, N. M. Kiselev, S. A. Klimin, V. N. Galkin

       Background: Gastric cancer (GC) is one of the most common malignancies which requires aggressive combined treatment with a high incidence of complications. The search for modifiable risk factors or predictors of complications’ development is ongoing.   We aimed to investigate the prognostic value of cachexia in patients with resectable GC.   Materials and methods: A multi-center retro-prospective cohort study included data of 144 GC patients who underwent potentially curative gastrectomy between 2019 and 2023. Cachexia and sarcopenia were diagnosed according to the most recent consensus definitions. Сachexia was defined according to the international consensus criteria as the loss of ≥ 5 % of weight in 6 months or the loss of 2 % body weight in the presence of sarcopenia or BMI < 20 kg / m2. To assess the presence of sarcopenia we used Prado criteria (52.4 cm2 / m2 for men and 38.5 cm2 / m2 for women) and Martin criteria (41 cm2 / m2 for women and 43 cm2 / m2 for men with a BMI < 25 kg / m2 and 53 cm2 / m2 with a BMI > 25 kg / m2) for L3 skeletal-muscle index. The 30-day incidence of postoperative complications and 90-day mortality were evaluated.   Results: There were 57 (39.5 %) patients with cachexia. Cachexia was more prevalent in patients with TNM stage III (42.1 % vs 24.1 %, p = 0.023) and sarcopenic patients (measured by skeletal muscle mass, 49.1 % vs. 18.3 %, p < 0.001, as well as dynamometry, 14.3 % vs. 0 %, p = 0.006). Multivariate analysis revealed that cachexia was a significant predictor of postoperative complications (ОR = 2.208, 95 % CI 1.051–4.638, p = 0.036) and surgical site infection (OR = 3.916, 95 % CI 1.146–13.3874, p = 0.029). The 90-day mortality rate was higher among patients with cachexia (10.5 % vs. 2.3 %, p = 0.039).   Conclusion: Preoperative cachexia is a potentially modifiable predictor of complications after gastric cancer surgery which may help to identify high-risk patients for proactive multimodal рrehabilitation.

  • Open Access

    Perioperative chemotherapy and morphological response in the treatment of gastric cancer: A retrospective study

    by Nikolay M. Kiselev, Sergey A. Klimin, Yan I. Kolesnik, Roman S. Kokorin, Erkin А. Ashimov, Victoria Y. Elagina, Irina S. Shumskaya, Vladimir E. Zagainov, Sergey V. Gamayunov, Елагина Виктория Юрьевна, et al.

    Aim. To analyze the treatment (8 cycle FLOT + surgery) to search for predictors of tumor pathomorphosis, assess the impact of chemotherapy on treatment results, and identify other factors that significantly influence treatment results. Materials and methods. Included 119 patients who underwent perioperative chemotherapy (FLOT) in combination with surgery in 2023 on the basis of the Nizhny Novgorod Regional Clinical Oncological Dispensary. This study consisted of two blocks: Identification of relationships between the analyzed parameters and the pathomorphological response, the development of postoperative complications. Analysis of overall and disease-free survival (DFS). In the analysis of nominal indicators, the first step was to use χ2 Pearson and Fisher's exact test. At the second stage, when statistical significance was achieved, the strength of the relationship was calculated for variables with two levels of the factor – Cramer’s V on the Rea Parker scale, odds ratio (OR) with a 95% confidence interval (CI), for variables with more than two factors, post-hoc analysis was performed with Benjamini–Hochberg correction for multiple comparisons. All quantitative indicators in the published sample have a distribution other than normal. The measure of central tendency is the median with 25th and 75th percentiles. When comparing two groups of quantitative indicators, the Mann–Whitney test was used; when comparing a larger number of groups, the Kruskal–Wallis test was used with post-hoc analysis using the Dunn test (if statistically significant differences were achieved at the first stage). Results. Analyzing the relationship between neo-adjuvant chemotherapy according to the FLOT regimen and the presence of response (TRG I–II), there was a lack of respondents in the subgroup who received neo-adjuvant chemotherapy according to regimens other than FLOT (p=0.019). Patients with stage I disease have a comparatively higher response rate to treatment compared with patients with ≥ stage III disease (post-hoc p-value=0.006). In the group of respondents there are fewer patients with positive lymph nodes compared to the group that did not respond to treatment (8.7% and 91%), the result is statistically significant (p-value 0.001). The presence of a response (TRG I–II) statistically significantly reduces the chance of positive tests by 7.30 times – OR 0.137 (95% CI 0.044–0.421). When conducting a subgroup analysis, the median age of patients with complications of types I–IIIa by Clavien–Dindo is statistically significantly lower compared to complications of types IIIb–V. There was no statistically significant relationship between tumor differentiation and response to treatment (p=0.3). When analyzing overall survival, there was a statistically significant increase in the risk of death with an increase in the number of postoperative days by 1 by 1.134 times or 13.4% (p=0.004). An increase in the number of metastatic lymph nodes by 1 increased the risk of death by 1.091 times or 9.1% (p=0.017). When analyzing DFS, a statistically significant increase in the risk of progression was revealed with an increase in the degree of pathomorphosis according to Mandard by 1 degree (starting from I) by 1.423 times or by 42.3% (p=0.042), an increase in the degree of pN-status by 1 (starting from N1) by 1.290 times or by 29.0% (p=0.011), an increase in the number of postoperative days by 1 by 1.099 times or by 9.9% (p=0.025). When analyzing the overall survival of the subgroup who received adjuvant chemo, there was a statistically significant increase in the risk of death in the subgroup of patients with adjuvant cgemo with an increase in the number of metastatic nodes by 1 by 1.087 times or by 8.7% (95% CI 1.009–1.172; p=0.029). When analyzing DFS of the subgroup who received adjuvant chemo, there was a statistically significant increase in the risk of progression in the subgroup of patients who received adjuvant chemo with an increase in the degree of pN status by 1 (starting from N1) by 1.252 times or 25.2% (p=0.040). When determining the effect of adjuvant chemo on overall survival and DFS using the Cox regression method, no statistically significant results were obtained. However, taking into account the p-value close to 0.05, the regression coefficient and most of the 95% CI (less than 1), it can be assumed that conducting adjuvant chemo reduces the risks of death and disease progression, and to achieve statistically significant results, a larger number of and observation time, number of outcomes. Conclusion. Neo-adjuvant FLOT is associated with a large number of TRG I–II in patients with an early stage of the disease in comparison with advanced forms of the disease. There was no effect of tumor differentiation or its histological subtype on the degree of TRG. Perioperative chemotherapy does not increase the incidence or severity of postoperative complications. Metastatic lesions of the lymph nodes significantly worsen overall survival and DFS; in the group of patients with TRG grade I–II, the frequency of metastatic lymph node lesions is lower compared to patients with TRG III–V. There is no significant data on the need for adjuvant chemo in the presence or absence of pathomorphosis, however, it can be assumed that performing adjuvant chemo reduces the risks of death and disease progression.


  • Open Access

    Determination of the Ki-67 threshold value for predicting lymph nodes involvement in patients with gastric cancer

    by Е. А. Ashimov, D. А. Chichevatov, V. V. Radovsky, Е. А. Kolesnikova, S. А. Klimin, S. V. Gamayunov, V. Е. Zagainov, N. М. Kiselev

    The search for biological markers to assess metastatic involvement of the lymph nodes in gastric cancer is one of the key steps in determining treatment tactics. The role of Ki-67 as a marker of cell proliferation in gastric cancer remains relevant. The aim of our study is to determine the Ki-67 threshold value for predicting the lymph nodes metastases. A retrospective analysis of 154 patients with gastric cancer showed an independent and statistically significant relationship between the depth of tumor invasion T (p = 0.002), the differentiation grade G (p = 0.010), the value of the Ki-67 index (p < 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p >< 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients>< 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p < < 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients >0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients with Ki-67 > 45 %, we found that the median OS was 32 months [HR 2.2; 95 % CI 1.2–3,9; p = 0.005], while it was not reached in the group with Ki-67 < 45 %.A Ki-67 level of ≥ 45 % is the optimal threshold for determining the likelihood of lymph node metastasis in gastric cancer.